Companies › Shanghai Jiatan Pharmatech
2 active drug programs in 4 registered trials: 2 Phase 1, 1 Phase 3, 1 Phase 2; Infectious disease, Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Sudapyridine (WX-081) Tuberculosis antibiotic - mechanism of action not specified in trial registry | – | Phase 3 | Rifampin-Resistant Pulmonary Tuberculosis; TB | – |
| WX390 STK11 inhibitor | STK11 | Phase 2 | Gastric Type Adenocarcinoma (GAS) With STK11 Mutation; Solid Tumor | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06117566 | WX390 | Phase 1 | Solid Tumor | Oncology | Nov 2025 |
| NCT06701110 | Sudapyridine (WX-081) | Phase 1 | TB | Infectious disease | Dec 2025 |
| NCT05824871 | Sudapyridine (WX-081) | Phase 3 | Rifampin-Resistant Pulmonary Tuberculosis | Infectious disease | Dec 2025 |
| NCT06124963 | WX390 | Phase 2 | Gastric Type Adenocarcinoma (GAS) With STK11 Mutation | Oncology | Dec 2026 |
–
Shanghai Bovax Biotechnology Cantex Pharmaceuticals The Skin Center Dermatology Group Tetraphase Pharmaceuticals Amivas
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.